AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Update: AbbVie headquarters building in California

Drug Development

AbbVie’s Skyrizi Outperforms J&J’s Stelara in Late-Stage Crohn’s Disease Trial

Continuing its clinical win streak, AbbVie’s Skyrizi showed signs of superiority against Johnson & Johnson’s Stelara in topline data from a head-to-head Phase III Crohn’s disease study.

September 13, 2023

2 min read

Tristan Manalac

Pictured: AbbVie Corporate Office/iStock, vzphotos

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

As biosimilars and next-generation treatments for Crohn’s disease enter the market, AbbVie will be knocked from its place of longtime dominance, contends data and analytics firm GlobalData.

September 8, 2023

3 min read

Kate Goodwin

AbbVie Removes Two Early-Stage Cancer Assets from Pipeline

The company appears to be terminating the development of two Phase I antibody-drug conjugates in cancer, ABBV-011 and the Pfizer-partnered ABBV-647.

August 24, 2023

2 min read

Tristan Manalac

Pictured: Dubai skyline/Courtesy, iStock, MAGNIFIE

Business

Abu Dhabi, Dubai Serve as Gateway to International Markets for Biopharma

Burjeel Holdings and BridgeBio Pharma ink partnership deal in rare genetic diseases with a plan to set up headquarters in Abu Dhabi.

July 11, 2023

4 min read

Lisa Munger

Pictured: Pre-filled injector device/iStock, sunny

First Round of Humira Biosimilar Launches in US

AbbVie’s Humira will now face competition from new biosimilars, including Boehringer Ingelheim’s Cyltezo, Celltrion’s Yuflyma, Organon and Samsung’s Hadlima, and Sandoz’s Hyrimoz.

July 3, 2023

2 min read

Tristan Manalac

Pictured: AbbVie sign on a building/courtesy of Ad

Drug Development

AbbVie, Genmab Bi-Specific Lymphoma Data Tee Up Potential Challenge to Roche Drug

Phase I/II data on AbbVie and Genmab’s recently approved bi-specific antibody in a second cancer indication positions them to talk to regulators about filings to challenge Roche’s Lunsumio.

June 29, 2023

2 min read

Nick Paul Taylor

Pictured: Analyst pointing to stock chart / iStock

Drug Development

MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data

Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.

June 27, 2023

2 min read

Kate Goodwin

Pictured: T cells attacking and killing cancer cel

FDA

Roche, AbbVie to Compete for Lymphoma Market Share with New BsAbs

With Roche’s FDA approval on Thursday, both companies’ bispecific antibodies will hit the market this summer for relapsed or refractory diffuse large B-cell lymphoma.

June 16, 2023

3 min read

Kate Goodwin

Pictured: Judicial gavel and scales of justice/Cou

Policy

AbbVie Files Patent Infringement Lawsuit Against BeiGene’s Brukinsa

The pharma company alleges that BeiGene’s Brukinsa patent, issued on Tuesday, infringes on its patent for Imbruvica to treat patients with slow-growing blood cancer.

June 15, 2023

2 min read

Alejandra Manjarrez

JOBS